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Aim. To investigate whether the cisplatin treatment of C6 rat glioma in vivo impacts the copy number altera-
tions (CNAs), proliferation and colony formation effi ciency (CFE) of tumor-derived cisplatin-resistant cells. 
Methods. The glioma modeling was performed by means of intracerebral stereotactic implantation of rat gli-
oma C6 cells into the striatum region of rats. The rats received 20 % dimethyl sulfoxide DMSO (C6R1) or 
cisplatin (C6R4CIS and C6R5CIS) injected intraperitoneally (5 mg/kg) three times per week. After 10 injec-
tions, gliomas were resected and the cells were cultured for in vitro analysis. CNAs were analyzed by array 
comparative genome hybridization, proliferation by direct cell counting in hemocytometer, CFE by soft agar 
assay. Results. No signifi cant changes in the CNAs and CFE of cisplatin-treated rat glioma C6R4CIS and 
C6R5CIS cell lines were observed compared to the vehicle-treated control C6R1 cells. However, C6R5CIS 
but not C6R4CIS had a reduced proliferation. Interestingly, both cisplatin- and vehicle-treated brain-grown 
cells had a reduced proliferation and CFE in comparison to the parental C6 cells. Conclusions. Despite numer-
ous reports on the destabilizing effects of cisplatin on genome and phenotype, the cisplatin treatment of C6 
cells in vivo did not affect genome stability, CFE, and had an inconsistent effect on the proliferation in vitro. 
The rat brain microenvironment may potentially impact the growth characteristics of rat glioma cells. 
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Introduction
Cisplatin (also called cisplatinum or cis-diam mi-
nedichloroplatinum(II) is a platinum inorganic coor-
dination compound with a square planar geometry. It 
is chemically inert until one or both of its chloride 
atoms are displaced spontaneously by water mole-
cules into the cytoplasm due to the relatively low 
concentration of chloride ions in the cytoplasm ver-
sus the extracellular space. Mono-/bi-aquated forms 
of cisplatin are highly electrophilic and form cova-
lent bonds with methionine and cysteine-containing 
peptides. Cisplatin binds with high affi nity to DNA, 
especially to nucleophilic N7 sites on purines, pro-
moting the formation of protein-DNA complexes as 
well as intra- and inter-strand DNA adducts. Thus, 
cisplatin exerts its cytostatic/cytotoxic effects in both 
nuclear and cytoplasmic compartments with the pri-
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mary role of the latter as high cytotoxicity was ob-
served in enucleated cells [1–2] The cisplatin treat-
ment resulted in the inhibition of mitochondrial res-
piration and effl ux of calcium from the mitochon-
dria, induced endoplasmic reticulum stress, reactive 
oxygen species formation and oxidative stress, lead-
ing to the depletion of reduced glutathione (GSH) 
and nicotinamide adenine dinucleotide (NADH) and 
peroxidation of polyunsaturated lipids and proteins 
(reviewed in [1, 2]). 
Cisplatin has been used in clinics since the 70s of 
the XX century for the treatment of multiple types of 
solid cancers. Noteworthy, cisplatin is signifi cantly 
effi cient only against germ cell cancers, resulting in 
a durable complete remission in >80 % of the pa-
tients; the biological reasons of this are still not com-
pletely understood. In contrast, the clinical response 
elicited by cisplatin in the patients affected by other 
solid tumors is very temporary, and the use of cispl-
atin-based chemotherapeutic regimens is restricted 
due to intrinsic or acquired resistance as well as con-
siderable systemic side effects [1, 2]. 
The glioma clinical trials also demonstrated a low 
effi cacy or even inferior outcome in the high-grade 
glioma patients after the treatment with cisplatin-ba-
sed chemotherapy. On the contrary, the in vivo mod-
els showed that the treatment with cisplatin or cispl-
atin-loaded mAbCx43- or BSAT1-conjugated nano-
gels signifi cantly inhibited rat glioma C6 and 101/8 
tumor growth and increased survival of animals [3, 
4]. Similarly, a combination of cisplatin with other 
therapeutic approaches demonstrated a high inhibi-
tory effect in the in vivo glioma models [5–7]. The 
reason for this obvious discrepancy is that the drug-
mediated stress may actually foster the tumor evolu-
tion by both selecting genetic variations and generat-
ing novel variations through the induction of genome 
reorganization [8–13]. An increase in chromosomal 
aberrations during and after chemotherapy was 
found to associate with an increased tumor aggres-
siveness [9]. The ability of cisplatin to induce chro-
mosome abnormalities has been known since the 
time of its approval for the clinic use [14]. For exam-
ple, the cisplatin treatment induced a signifi cant in-
crease in the chromosome breakage at all stages of 
spermatogenesis in Drosophila melanogaster [15]. In 
Saccharomyces cerevisiae, the cisplatin treatment in-
duced chromosomal aberrations, although the degree 
of instability was lower than that induced by other 
DNA damaging agents (e.g., bleomycin, camptothe-
can, or γ-irradiation) [16]. A comparison of the paren-
tal human ovarian cancer cells to sublines selected for 
resistance to cisplatin revealed that the acquired re-
sistance to cisplatin was associated with the numerical 
and structural chromosome aberrations and substan-
tial copy number alterations (CNAs) [17, 18].
The intrinsic or acquired resistance is another 
signifi cant contributor to the therapy failure. The 
cell culture models revealed that cisplatin resist-
ance is attained by several complex molecular and 
cellular mechanisms. They include but are not con-
fi ned to the activation of multiple signal transduc-
tion pathways, reduction of cisplatin accumulation 
by either active effl ux or impaired infl ux, detoxifi -
cation by cellular antioxidant systems, increase in 
DNA damage repair, inactivation of apoptosis pa-
thway, alterations of the membrane protein traf-
fi cking due to the cytoskeleton defective organiza-
tion, activation of the epithelial-mesenchymal tra-
nsition, overexpression of chaperones, deregulati-
on of miRNA and transcription factors, the impact 
of stroma cells and components of extracellular 
matrix [1, 2, 19]. An overall abnormal phenotype 
after the cisplatin treatment results from an in-
crease in DNA mutation load and profound chang-
es in the DNA methylome, transcriptome, prote o-
me, metabolome and kinome (kinase activity pro-
fi le) [20]. Altogether, these data reveal a complex 
multilevel mechanism of tumor cells self-defence 
against the cisplatin cytotoxicity.
Here, we have investigated whether the cisplatin tre-
atment of C6 rat glioma in vivo impacted CNAs, pro-
liferation and colony formation effi ciency (CFE) of 
the tumor-derived cisplatin-resistant cells in vitro. 
Materials and Methods
Cell lines
Rat glioma C6 cell line was grown in DMEM (Hy 
Clo ne, Thermo Scientifi c, UK) supplemented with 
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10 % FBS (HyClone, Thermo Scientifi c) and 100 μg/
ml penicillin/100 u/ml streptomycin (Sigma, USA) 
in the environment of 95 % air / 5 % CO2. 
Cisplatin treatment of rats 
with intracranial C6 gliomas 
The animals were kept and treated in accordance 
with the Guidelines on Laboratory Practices ado-
pted by the Ministry of Health of the Russian Fe-
de ration (Order 267, 19 June 2003), and the prin-
ciples of bioethics adopted by the European Con-
vention for the Protection of Vertebrate Animals 
Used for Ex perimental and Other Scientifi c Pur-
poses (Stras bourg, 1986). A glioma modeling and 
tumor volume measurement were performed as 
described previously [3, 4]. After fi ve days of C6 
glioma cells inoculation, rats received 20 % 
DMSO (n = 1, namely C6R1), which served as a 
solvent for drug, or cisplatin (n = 2, namely 
C6R4CIS and C6R5CIS) injected intraperitoneal-
ly three times per week at a dose of 5 mg/kg. Rats 
were sacrifi ced after 10 injections of cisplatin/
DMSO. Gliomas were harvested aseptically and 
disaggregated mechanically. The cell suspension 
was seeded on plates with growth medium. Cells 
were used at passage numbers 3–10 for analysis.
Array comparative
genome hybridization (aCGH)
Total DNA was isolated using NucleoSpin Blood 
DNA extraction kit (Macherey-Nagel, Germany) ac-
cording to the manufacturer’s instructions. DNA qua-
lity was assessed using NanoDrop 1000 Spec tro pho-
tometer (Thermo Scientifi c, USA). aCGH was per for-
med as detailed previously [12]. Rat cell lines we re 
analyzed on 180K microarray (Agilent Technologies, 
Santa Clara, CA, USA). Image analysis was carried out 
with Agilent CytoGenomics, edition 2.9.2.4 (Agilent). 
Cell proliferation analysis
Cells were seeded onto 6 cm dishes at the density 1 × 
× 104 and grown in the high-glucose DMEM with 
10 % FBS. On the 7th day of seeding, medium was 
carefully removed; cells were washed with PBS, 
trypsinized, harvested, incubated with trypan blue, 
and calculated using a hemocytometer. The test was 
repeated at least three times.
Soft agar colony formation assay
5 × 103 cells were placed in 1.5 ml of 0.35 % / 10 % 
FBS/DMEM low gelling temperature agarose (Gib-
co, Life Technologies, Grand Island, USA) with 
Fig. 1. Brain magnetic resonance imaging (MRI) using a ClinScan MRI scanner with fi eld strength of 7T was carried out for C6 rat 
gliomas after 2 weeks of cisplatin treatment. A morphometric analysis of C6 gliomas after this period of time showed that tumor 
volumes of C6R1, C6R4CIS and C6R5CIS gliomas were ≈80 mm3, ≈ 35 mm3 and ≈ 60 mm3, respectively. Rats with C6 gliomas 
received cisplatin at a dose of 5 mg/kg (C6R4CIS and C6R5CIS) or 20% DMSO (control C6R1), injected intraperitoneally three 
times per week. The animals were sacrifi ced after 10 injections of cisplatin/DMSO
C6R1 C6R4CIS C6R5CIS
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DMEM supplemented with 10 % FBS. 0.35 % top 
agarose was poured on 1.5 ml of solidifi ed 0.5 % 
base agarose/10 % FBS/DMEM. Cells were seeded 
in triplicates in 35-mm dishes of 6-well plates and 
grown at 37 C for three weeks to allow colony for-
mation. Colonies were visualized by staining with 
0.005 % crystal violet, photographed, and counted 
using OpenCFU software [21]. Test for each cell line 
was repeated three times.
Statistics
The Student’s t-test was used to analyze the signifi -
cance of variability between the results of each group 
and its corresponding control (Statistica 7 Software, 
San Diego, USA). Results with *P < 0.05, **P < 
< 0.01, and ***P < 0.001 were considered signifi -
cant. All experimental data are reported as the mean 
and the error bars represent the experimental stand-
ard error (± standard deviation, SD). 
Results and Discussion
Cisplatin-treated C6R4CIS, C6R5CIS and vehicle-
treated control C6R1 cell lines were established from 
the parental C6 cell line by injecting cisplatin (or a 
vehicle 20 % DMSO) intraperitoneally three times 
per week at a dose of 5 mg/kg. A morphometric analy-
sis of C6 gliomas after two weeks of treatment showed 
that tumor volumes of C6R1, C6R4CIS and C6R5CIS 
gliomas were ≈ 80 mm3, ≈ 35 mm3 and ≈ 60 mm3, 
respectively (Figure 1). After 10 injections, the vehi-
cle-treated control and surviving cisplatin-resistant 
cells were tumor-derived and analyzed in vitro. 
Despite the numerous reports on genotoxic effects of 
cisplatin [2,15–18,22], the copy number alterations 
(CNAs) of parental C6 cells, control C6R1, and cispl-
atin-treated C6R4CIS and C6R5CIS cell lines were 
essentially si milar with minor variations in the gene-
depleted chro mosome loci. The major detected aber-
rations we re loss of 16q12.1-q24.3 and gain of 
7p21.1-q31.1 (Fi gu re 2). It should be noted that in 
contrast to conventional cytogenetics/karyotyping, 
aCGH is based on the average profi le of genetic 
changes in thousands of cells; this underestimates 
structural chromosome com plexity and heterogeneity 
of tumor cells [12, 23].
Fig. 2. Chromosomal ideograms with the drawn color bars ali-
gned along chromosomes show the areas of genetic gain/loss. 
Red bars represent areas of copy number loss, whereas blue bars 
represent areas of copy number gain. The major detected aberra-
tions were loss of 16q12.1-q24.3 and gain of 7p21.1-q31.1 
(marked by arrows). CNAs were identifi ed by array comparative 
genome hybridization (aCGH)
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There was no difference in proliferation rates be-
tween C6R1 and C6R4CIS; however, C6R5CIS had 
a moderately reduced proliferation (Figure 3). Fur-
ther, no difference in CFE between C6R1 and C6 
R4CIS or C6R5CIS cells was observed (Figure 4). 
The data that cisplatin treatment reduces tumor growth 
and increases survival of C6 glioma-bearing rats [4] 
but does not obviously infl uence chromosome stabil-
ity and in vitro growth characteristics of C6 cells, 
which survived/resisted cisplatin treatment, suggest 
that cisplatin has a cytostatic rather than profound 
genotoxic and cytotoxic effects on C6 cells in vivo. 
Interestingly, we have observed reduced prolifera-
tion and CFE of the control and cisplatin-treated 
cells in comparison to the parental C6, suggesting 
that the rat brain microenvironment may select for 
slow-dividing C6 cells. The alternative explanation 
is that in brain, C6 cells are adapted to different nu-
trients, oxygen levels, growth-stimulating and other 
factors; therefore they undergo a stress when reintro-
duced to in vitro culture. Finally, we cannot exclude 
an effect of a vehicle (20 % DMSO) as DMSO treat-
ment in vivo induced cytotoxicity at certain concen-
trations ([24] and refs. herein). However, we have 
injected substantially lower DMSO volume and con-
centration than those used in these studies.
Previously, we and others have shown that cispla-
tin or combination of cisplatin with other therapeutic 
approaches demonstrated a high inhibitory effect in 
in vivo models, including rat glioma C6 and 101/8 
tumor models [3–7]. Unfortunately, the encouraging 
laboratory observations do not agree with the effi -
ciency of treatment of the high-grade glioma pa-
tients. There were many frustrated clinical trials as 
exemplifi ed below that ultimately did not justify the 
addition of cisplatin to the chemotherapeutic regi-
men of the high-grade glioma patient treatment. 
Cisplatin and carmustine followed by radiation did 
not improve median survival, survival at one year, or 
time-to-progression of patients with newly diag-
nosed glioblastoma. Furthermore, this treatment was 
associated with more serious toxicities than standard 
therapy [25]. Similarly, cisplatin administered con-
currently with carmustine and radiotherapy resulted 
in a higher toxicity but provided no signifi cant im-
provement in survival [26]. The estimation of re-
sponse rate, the rate of disease stabilization, and the 
probability of one-year survival of the patients with 
high-grade glioblastomas who received radiotherapy 
concurrently with cisplatin/carmustine chemothera-
py did not support the routine use of concurrent cis-
platin and carmustine [27]. The progression-free sur-
vival and overall survival of glioblastoma patients 
treated with the radiotherapy, cisplatin and carmus-
tine were comparable with those obtained with the 
radiotherapy and temozolomide but the toxicity was 
more frequent and persistent. The results argued 
against future use of this combination in the treat-
ment of patients with glioblastoma [28]. Although 
the median survival time with the cisplatin/nimus-
tine neoadjuvant chemotherapy followed by the ra-
diotherapy and adjuvant temozolomide was incre-
ased in patients with newly diagnosed glioblastoma, 
a high frequency of serious hematological toxicity 
limited its use [29]. Further, none real advantage of 
neoadjuvant cisplatin and etoposide after surgery 
Fig. 3. Cisplatin treatment of C6 glioma in vivo did not consist-
ently affect proliferation of tumor-derived C6 cells. However, 
signifi cantly reduced proliferation of control C6R1 and cispla-
tin-treated C6R4CIS and C6R5CIS cell lines in comparison to 
parental C6 was observed. To analyze the rate of proliferation, 
cells were seeded at the density 1 × 104 cells. The number of 
cells was calculated after 7 days of growth. All experiments we-
re performed at least three times and results are presented as the 
means ± SD. *P < 0.05, ***P < 0.001, NS = non-signifi cant
  C6             C6R1       C6R4CIS      C6R5CIS
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and prior to radical radiotherapy was obtained in the 
treatment of high-grade gliomas if compared with 
the standard adjuvant chemotherapy [30]. Cisplatin 
combined with cytosine arabinoside and hydroxyu-
rea did not improve the six-month survival rate in 
patients with relapsed or progressive high-grade 
glioblastomas. Signifi cant hematological toxicities 
were observed [31]. Finally, the recent medulloblas-
toma trial demonstrated that the cumulative cisplatin 
dose was not associated with overall survival [32]. 
Recently, we have shown that the long-term treat-
ment of tumor cell lines with a DNA damaging drug 
temozolomide, which is widely used for glioma pa-
tients, promoted the clonal and non-clonal chromo-
some aberrations, CNAs and diverse phenotype 
changes affecting survival, CFE, migration, and in-
vasion ([12], Stepanenko et al., in preparation). 
Furthermore, many chemotherapeutics, which have 
been used previously or are exploited currently in 
clinic for cancer treatment, were evidenced to in-
duce/promote the chromosome instability/aneuploi-
dy in rodent and human cells. These include nocoda-
zole, a microtubule-depolymerizing agent; paclitaxel 
and taxol, microtubule-stabilizing agents; platinum 
compounds cisplatin and carboplatin; etoposide and 
doxorubicin, topoisomerase I and II inhibitors; bleo-
mycin that causes breaks in DNA; actinomycin D 
which interferes with transcription and replication; 
5-fl uorouracil, a thymidylate synthase inhibitor; im-
atinib and nilotinib, multiple kinase inhibitors; ra-
pamycin, an mTOR inhibitor; tamoxifen, an estro-
gen receptor inhibitor, and many others (reviewed in 
[9]). This should be seriously taken into account as 
the cancer cell genome instability, promoted by 
drug-mediated system stress, fosters genomic, epi-
genetic, and non-genetic heterogeneity, intensifi es 
profound transcriptome and proteome changes, and 
rewires metabolic and signaling network, altogether, 
giving rise to the diverse drug-resistant phenotype 
variants. The genome instability signifi cantly corre-
lates with inherent and acquired multi-drug resist-
ance, and chemoresistance acquisition is accompa-
Fig. 4. Cisplatin treatment of C6 glioma in vivo did not affect colony formation effi ciency (CFE) in soft agar of tumor-derived C6 
cells. However, reduced CFE of control C6R1 and cisplatin-treated C6R4CIS and C6R5CIS cell lines in comparison to parental C6 
was observed. For colony formation, 5×103 cells were seeded in soft agar and grown for 3 weeks. Colonies were stained with crystal 
violet and calculated using OpenCFU software. (A) The representative photographs of plate wells with stained colonies are shown. 
(B) The graph compares CFE of the designated cell lines. All experiments were performed three times and results are presented as 
the means ± SD. *P < 0.05, NS = non-signifi cant
A B
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nied by newly evolved chromosome imbalances (re-
viewed in [8–11, 13, 33–38]).
Conclusion
Despite the numerous reports on genome and pheno-
type destabilizing effects of cisplatin, we have not ob-
served any changes in CNAs, CFE and consistent 
changes in proliferation in vitro of in vivo cisplatin-
treated rat glioma C6 cells. However, we have revealed 
that brain-grown C6 cells have a reduced proliferation 
rate and CFE in comparison to the parental C6 cell 
adapted to grow in vitro for decades. The versatile com-
plex mechanisms of intrinsic/acquired resistance and 
considerable systematic side effects signifi cantly re-
duce the effi cacy of cisplatin in clinic. The failure of 
phase II and III clinical trials with the cisplatin-based 
therapeutic regimens does not support the use of cispla-
tin in further high-grade glioma trials. 
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Терапія цисплатином клітин С6 гліоми щура
in vivo не вплинула на зміни числа копій
хромосомних локусів та патерн росту виділених
з пухлини резистентних клітин 
О. А. Степаненко, В. П. Баклаушев,
Є. С. Васецький, В. В. Дмитренко
Мета. Перевірити, чи впливає терапія цисплатином клітин 
С6 гліоми щура in vivo на зміни числа копій хромосомних 
локусів, проліферацію і ефективність формування колоній 
цисплатин-нечутливими клітинами. Методи. Моделювання 
гліоми було виконано за допомогою внутрішньомозкової сте-
реотаксичної імплантації щурячих клітин гліоми С6 в область 
смугастого тіла щура. Щурам вводили внутрішньоочере-
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винно 20 % ДМСО (C6R1) або 5 мг/кг цисплатин (C6R4CIS 
і C6R5CIS) три рази на тиждень. Після 10 ін’єкцій, клітини 
гліоми були вилучені і поміщені в ростове середовище для 
подальшого аналізу in vitro. Зміни кількості копій хромо-
сомних локусів було проаналізовано за допомогою порів-
няльної геномної гібридизації, аналіз проліферації здій снювали 
прямим підрахунком клітин в гемоцитометрі, а ефективність 
формування колоній (ЕФК) – аналізом росту в м’якому ага-
рі. Результати. Ніяких істотних змін числа копій хромосом-
них локусів, проліферації та ЕФК між лініями C6R4CIS, 
C6R5CIS і C6R1 не спостерігалося. Однак C6R5CIS, але не 
C6R4CIS лінія знизила проліферацію при порівнянні з C6R1. 
Цікаво, що клітинні лінії C6R4CIS, C6R5CIS і C6R1 мають 
нижчий рівень проліферації та ЕФК при порівнянні з вихід-
ною батьківською лінією C6. Висновки. Незважаючи на 
численні повідомлення про дестабілізуючий вплив циспла-
тину на геном і фенотип клітин, терапія цисплатином С6 
гліоми щура in vivo не вплинула на геномну стійкість, ЕФК 
та мало суперечний вплив на проліферацію клітин in vitro. 
Мікрооточення щурячого мозку потенційно може впливати 
на ростові характеристики пухлинних клітин гліоми.
Ключов і  слова: анеуплоїдія, хромосомна нестабільність, 
лікарська стійкість, еволюція пухлини, гетерогенність.
Терапия цисплатином клеток С6 глиомы
крысы in vivo не повлияла на изменения числа
копий хромосомных локусов и паттерн роста 
выделенных из опухоли резистентных клеток 
А. А. Степаненко, В. П. Баклаушев,
Е. С. Васецкий, В. В. Дмитренко
Цель. Проверить, влияет ли терапия цисплатином С6 глио-
мы крысы in vivo на изменения числа копий хромосомных 
локусов, пролиферацию и эффективность образования ко-
лоний цисплатин-нечувствительными клетками. Методы. 
Моделирование глиомы было выполнено с помощью сте-
реотаксической имплантации аллогенных крысиных клеток 
глиомы С6 в область каудопутамена. Крысам с эксперимен-
тальной глиомой вводили внутрибрюшинно 20 % ДМСО 
(C6R1) или 5 мг/кг цисплатин (C6R4CIS и C6R5CIS) три 
раза в неделю. После 10 инъекций, клетки глиомы были 
изъяты и помещены в ростовую среду для дальнейшего ана-
лиза in vitro. Изменение числа копий хромосомных локусов 
было проанализировано с помощью сравнительной геном-
ной гибридизации, анализ пролиферации осуществляли пря-
мым подсчетом клеток в гемоцитометре, а эффективность 
образования колоний (ЭОК) – анализом роста в мягком ага-
ре. Результаты. Никаких существенных изменений числа 
копий хромосомных локусов и ЭОК между линиями C6R4CIS, 
C6R5CIS и C6R1 не наблюдалось. Однако C6R5CIS, но не 
C6R4CIS линия снизила пролиферацию при сравнении с 
C6R1. Интересно, что клеточные линии C6R4CIS, C6R5CIS5 
и C6R1 имеют более низкий уровень пролиферации и ЭОК, 
чем исходная родительская линия C6. Выводы. Несмотря 
на многочисленные сообщения о дестабилизирующем вли-
янии цисплатина на геном и фенотипи клеток, терапия цис-
платином С6 глиомы крысы in vivo не повлияла на геном-
ную устойчивость, ЭОК и оказывала противоречивое дейс-
твие на пролиферацию in vitro. Микроокружение крысиного 
мозга потенциально может влиять на ростовые характерис-
тики опухолевых клеток глиомы.
Ключевые  слова: анеуплоидия, хромосомная нестаби-
льность, терапевтическая резистентность, эволюция опу хо-
ли, гетерогенность.
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